# A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma

> **NCT00930683** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 34 (actual)

## Conditions studied

- Scleroderma

## Interventions

- **DRUG:** MEDI-546
- **DRUG:** MEDI-546
- **DRUG:** MEDI-546
- **DRUG:** MEDI-546
- **DRUG:** MEDI-546
- **DRUG:** MEDI-546
- **DRUG:** MEDI-546
- **DRUG:** MEDI-546
- **DRUG:** MEDI-546

## Key facts

- **NCT ID:** NCT00930683
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-05
- **Final completion:** 2011-07
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2012-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00930683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00930683, "A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00930683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*